Page 325 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

12. COMPLEXES DUPLATINE 281

ZALUDOVA R. et al., DNA modifications by antitumor trans-PtCI,(E-iminoether)2], Mol.
Pharmacol., 1997, 52, 354-361.
BIERBACH U., FARRELL N., Structural and reactivity studies on the ternary system gua-
nine/methionine/trans-[PtCI,(NH,)L] (L = NH,, quinoline) : implications for the mecha-
nism of action of nonclassical trans-platinum antitumor complexes, J. Bio/. lnorg.
Chem. 1998, 3, 570-580.
BLASI P. et al., Cytotoxicity, cellular uptake and DNA bindlng of the novel trinuclear
platinum complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells,
Anticancer Res., 1998, 18, 3113-3117.
HOLFORD J. et al., ln vitro circumvention of cisplatin-resistance by the novel sterically
hindered platinum complex AMD473, Br. J. Cancer, 1998, 77, 366-373.
QUIROGA A.G. et al., Novel tetranuclear orthometalated complexes of Pd(II) and Pt(II)
derived from p-isopropylbenzaldehyde thiosemicarbazone with cytotoxic activity in
cis-DDP resistant tumor cell fines. Interaction of these complexes with DNA, J. Med.
Chem. 1998, 41, 1399-1408.
YABUSHITA H., Liposome-encapsulated CDDP for modification of pharmacokinetics
and tissue-distribution, in : Mech. Cisplatin Resist. lts Circumvention, Kikuchi Y., ed.,
Nova Science Publishers: Commack, New York., 1998, 225-230.
BARNARD C.F.J. et al., Development of an orally active platinum anticancer drug : JM-
216, Top. Biol. Inorg. Chem., 1999, 1, 45-71.
BIERBACH U. et al., Synthesis, structure, biological activity, and DNA binding of plati-
num(Il) complexes of the type trans-[PtCI,(NH,)L] (L = Planar Nitrogen Base). Effect of
L and Cis/Trans Isomerism on sequence specificity and unwinding properties obser-
ved in globally platinated DNA, Inorg. Chem., 1999, 38, 3535-3542.
BRABEC V. et a/., DNA modifications by a novel bifunctional trinuclear platinum phase 1
anticancer agent, Biochemistry, 1999, 38, 6781-6790.
FOKKEMA E., et a/., Phase Il study of oral platinum drug JM-216 as first-line treatment
in patients with small-cell lung cancer, J. Clin. Oncol., 1999, 17, 3822-3827.
LOWE G. et a/., Cytotoxicity of 2,2': 6',2"-terpyridineplatinum(ll) complexes against
human ovarian carcinoma, J. Med. Chem., 1999, 42, 3167-3174.
McGREGOR T.D. et al., Sequence-dependent conformational changes in DNA induced
by polynuclear platinum complexes, J. /norg. Biochem., 1999, 77, 43-46.
MONTERO E.I. et al., Preparation and characterization of novel trans-[PtCI,(amine)(iso-
propylamine)] compounds : cytotoxic activity and apoptosis induction in ras-transfor-
med cells, J. Med. Chem., 1999, 42, 4264-4268.
NATILE G. et a/., Trans-platinum compounds in cancer therapy : a largely unexplored
strategy for identifying novel antitumor latinum drugs, Top. Bio/. Inorg. Chem., 1999,
73-98, Chem. Abstr., 1999, 132, 116944.
OSKUI B. et al., Di- and trinuclear Pd(II) and Pt(II) complexes containing bridging 2,7-
disubstituted naphthyridines, lnorg. Chim. Acta, 1999, 287, 72-81.
PEREGO P. et al., A novel trinuclear platlnum complex overcomes cisplatin resistance in
an osteosarcoma cell system, Mol. Pharmacol., 1999, 55, 528-534.
PRATESI G. et al., A novel charged trinuclear platinum complex effective against cispla-
tin-resistant tumours : hypersensitivity of p53-mutant human tumour xenografts, Br.
J. Cancer, 1999, 80, 1912-1919.